Take a closer look at the changes in the original research market of six heavy-duty varieties: which products are fierce in "grabbing"? How did Hengrui, Qilu and Zhengda Tianqing perform?

In many developed countries, the price and market share of generic drugs will decrease significantly after the expiration of the original patent However, in China, many imported drugs still maintain high prices after patent failure, and the sales volume has not been significantly affected The original research drugs still occupy the market for a long time after the expiration of the patent, and the substitution of the generic drugs in our country is very difficult The main reason is the quality of the generic drugs and the weak position in the clinical application, bidding procurement and market competition for a long time Nowadays, the country has made a top-level design in the aspect of generic drugs replacing the original drugs From the State Council, the drug regulatory bureau to drug bidding everywhere, there are clear favorable policies for generic drugs that pass the consistency evaluation, and the state has established a list of listed drugs, which provides a better system guarantee for new drug innovation and generic drug research and development The generic drugs that are consistent with the quality and efficacy of the original research drugs shall be included in the catalogue of substitutable drugs with the original research drugs, marked in the instruction manual and label, and relevant information shall be released to the society in time, so as to facilitate the selection and use of medical staff and patients With the development of conformity evaluation of generic drugs, once the patent expires, domestic high-quality generic drugs will quickly replace the original products This paper analyzes the representative best-selling drugs in various treatment fields of domestic sample hospitals from 2012 to 2017, and compares the market share changes of original research drugs of foreign enterprises and domestic generic drugs in the past five years From the current data, although the market advantage of the original drugs such as clopidogrel, atorvastatin, moxifloxacin, esomeprazole, acarbose and capecitabine is still difficult to shake, it is worth noting that the market share of generic drugs such as moxifloxacin, esomeprazole and capecitabine has changed rapidly The proportion of atorvastatin generic drugs in the original research is less than 30% [pattern change] the share of generic drugs increased by 6.3% (2012-2017, the same below) Atorvastatin is a product approved by Pfizer in 1997 Its trade name is "Lipitor" It is used in the treatment of dyslipidemia It is one of the essential drugs after thrombus interventional therapy Its remarkable curative effect and rapid growth market are widely concerned by the global pharmaceutical industry Atorvastatin is the best-selling drug of Pfizer and the first blockbuster drug in the history of medicine that has accumulated and sold more than 100 billion dollars According to the statistics of the world's best-selling drugs, the sales volume of the drug exceeded 10 billion US dollars for seven consecutive years in 2004-2011 Its patents have been expired since 2011, and the market has declined rapidly In 2017, its sales volume was only USD 1.915 billion In 1999, domestic atorvastatin was first imitated on the market Lipitor entered China and became one of the fastest growing cardiovascular varieties Atorvastatin is the first drug in the blood lipid lowering market and the top three drug in the cardiovascular market According to the data of domestic sample hospitals, atorvastatin has maintained a high-speed growth trend from 2012 to 2017, and the amount of medication in 2017 reached 2.208 billion yuan In China, there are six manufacturers of the drug In 2017, the market pattern of sample hospitals is: Pfizer's sales of "Lipitor" is 1.628 billion yuan, accounting for 73.7%; Beijing Jialin pharmaceutical's sales of "alo" is 385 million yuan, accounting for 17.4%; Henan Tianfang pharmaceutical's sales of "Youjia" is 128 million yuan, accounting for 5.8%; other enterprises account for 3.1% Over the years, Pfizer's atorvastatin has been dominant in the market, accounting for more than 70% of the market share From the market data of 2012-2017, the share of Pfizer, the original research enterprise, decreased from 79.6% to 73.3%, and the total share of domestic generic pharmaceutical enterprises increased from 20.1% to 26.3% Clopidogrel's original research drug still accounts for 60% of the market [pattern change] the share of generic drugs increased by 9.8% Clopidogrel was jointly developed by Bristol Myers Squibb and Sanofi It was approved by FDA in 1997 and listed as "Plavix" This product is a milestone in the field of antithrombotic and antiplatelet aggregation Before the patent expires in 2012, the market is the second largest selling drug in the world after Lipitor Clopidogrel was developed and listed earlier in China In 2000, clopidogrel of Shenzhen xinlitai Pharmaceutical Co., Ltd was first approved to be registered for production, with the trade name of "Taijia" In September of the same year, clopidogrel of Sanofi Aventis and Bristol Myers Squibb was granted administrative protection in China In 2001, clopidogrel of Sanofi Aventis was approved to be listed in China under the trade name of "Plavix" According to the data of domestic sample hospitals, clopidogrel is one of the best-selling drugs at present, with a sales volume of 2.395 billion yuan in 2017 In China, there are three manufacturers of the drug In 2017, the market pattern of sample hospitals is: Sanofi Aventis "Plavix" sales is RMB 1.419 billion, accounting for 59.2%; xinlitai "Taijia" sales is RMB 722 million, accounting for 30.1%; Lepu pharmaceutical "Shuaike" sales is RMB 255 million, accounting for 10.6% The market share of clopidogrel of Sanofi Aventis is more than half From 2012-2017 market data, the share of Sanofi Aventis, the original research enterprise, decreased from 69.0% to 59.2%, and the total share of domestic generic pharmaceutical enterprises increased from 31.0% to 40.8% Acarbose accounts for nearly 30% of China, the United States and East China [pattern change] the share of generic drugs increased by 16% Acarbose was developed by Bayer, and the trade name is "betacarbose" This drug belongs to α - glucosidase inhibitor, which has a general reaction in the European and American markets, but has achieved unprecedented success in the Chinese market, ranking first in the domestic diabetes market for many years in a row At present, acarbose is still the first choice for postprandial blood glucose control According to the data of domestic sample hospitals, the sales volume of acarbose reached 1.09bn yuan in 2017 In China, there are three manufacturers of the drug In 2017, the market pattern of the sample hospital is as follows: Bayer's sales volume of "Baitangping" is 724 million yuan, accounting for 66.4%; Hangzhou, China, the United States and East China Pharmaceutical "caboping" sales volume is 317 million yuan, accounting for 29.1%; Sichuan LVYE Baoguang pharmaceutical "Beixi" sales volume is 49.74 million yuan, accounting for 4.6% At present, the original research drug Baitangping still accounts for more than 60% of the market share, and the domestic enterprises Hangzhou, Central America and East China have a better market performance According to the market data from 2012 to 2017, Bayer's share of the original research enterprise decreased from 82.4% to 66.4%, and the total share of domestic generic pharmaceutical enterprises increased from 17.6% to 33.6% The market growth of domestic generic moxifloxacin is significant [pattern change] the amount of generic drug reaches 36.4% and moxifloxacin is researched and developed by Bayer It was first listed in Germany in September 1999 and approved by FDA in the United States in December of the same year The product name is "baifule" The drug belongs to the fourth generation of ultra wide spectrum quinolones with strong antibacterial performance It has been used in clinical practice in many countries and regions In 2007, the global sales reached a peak of 1.03 billion US dollars In December 2002, moxifloxacin was approved to enter the Chinese market under the name of "baifule" At present, there are three domestic enterprises participating in the competition, involving tablets and injections According to the data statistics of domestic sample hospitals, the sales of moxifloxacin in 2017 was RMB 1.45 billion With the help of the huge market of anti infective drugs, the drug has become the fastest growing quinolones after being put on the market From the perspective of market structure, in 2017, Bayer's sales volume of "baifule" was 922 million yuan, accounting for 63.6% of the total; Nanjing Unitech pharmaceutical's sales volume of "baimeinuo" was 429 million yuan, accounting for 29.6% of the total; Chengdu Tiantaishan pharmaceutical's sales volume of moxifloxacin was 99.11 million yuan, accounting for 6.8% of the total Bayer has two dosage forms: tablet and injection Both Nanjing Youke pharmaceutical and Chengdu Tiantaishan pharmaceutical are injection In April 2013, CFDA approved the production and marketing of moxifloxacin API and xiaoshuizhen injection of Nanjing Youke pharmaceutical, breaking Bayer's monopoly pattern Since then, the growth rate of imported products has slowed down and that of domestic products has increased significantly From 2012-2017 market data, Bayer's share of the original research enterprise decreased from 100% to 63.6%, and the total share of domestic generic pharmaceutical enterprises was 36.4% Capecitabine, a tripod [pattern change] imitated drug, accounts for 27.5% of domestic enterprises Capecitabine is developed by Roche with the trade name of "Xeloda" It belongs to the oral fluoropyrimidine carbamate antitumor drug, which is mainly used to treat breast cancer and colorectal cancer Capecitabine's patent expired in December 2013 In the same year, Hengrui pharmaceutical and Qilu pharmaceutical won the first batch of generic pharmaceutical titles of the product Zhengda Tianqing obtained the production approval of the drug in early 2014 Capecitabine is the first-line fluoropyrimidine chemotherapy drug for patients with metastatic colorectal cancer According to the data of domestic sample hospitals, the drug sales reached 944 million yuan in 2017 In China, capecitabine has 4 manufacturing enterprises, the main dosage form of which is tablet In 2017, the market pattern of sample hospitals is as follows: Shanghai Roche pharmaceutical's "Xeloda" market accounts for 72.5%, Jiangsu Hengrui pharmaceutical's "aibin" for 10.6%, Qilu pharmaceutical's "Zhuolun" for 9.8%, and Zhengda Tianqing pharmaceutical's "first subsidiary" for 7.1% With the generic drugs of Hengrui pharmaceutical, Qilu pharmaceutical and Zhengda Tianqing entering the market, domestic capecitabine has an impact on the share of Roche's original research products According to the market data from 2012 to 2017, Roche's share of the original research enterprise decreased from 100% to 72.5%, and the total share of domestic generic pharmaceutical enterprises was 27.5% At present, capecitabine generic drugs have formed a three pronged trend of Hengrui medicine, Qilu medicine and Zhengda Tianqing It is the general trend to replace the original products Esomeprazole, led by Zhengda Tianqing, is an S-isomer of omeprazole The drug was first listed in Germany and the UK in 2000, with annual sales of about 5 billion US dollars from 2006 to 2011, and the patent expired in 2014 In 2003, esomeprazole of AstraZeneca was launched in China in the form of oral enteric coated tablets Before 2012, AstraZeneca monopolized the domestic market In 2013, Chongqing Laimei pharmaceutical enteric coated capsule obtained the production approval, breaking the monopoly situation of foreign enterprises In 2016, etomeprazole for injection of Zhengda Tianqing and aosaikang was approved According to the data of domestic sample hospitals, esomeprazole is the best-selling drug in the field of digestion As a proton pump inhibitor, it is widely used in a variety of peptic ulcer and bleeding diseases In 2017, its sales reached 1.216 billion yuan In China, there are four manufacturers of the drug In 2017, the market pattern of sample hospitals is as follows: AstraZeneca's sales volume of "nexin" is 974 million yuan, accounting for 80.1%; Zhengda Tianqing's sales volume of "azopine" is 140 million yuan, accounting for 11.6%; Chongqing's sales volume of "laimeishu" is 53.12 million yuan, accounting for 4.4%; Jiangsu's aosaikang's sales volume of "Aoxikang" is 48.3 million yuan, accounting for 4.4% Than 4% Because of the large market scale of proton pump inhibitors for injection, esomeprazole is highly sought after in the market According to the market data from 2012 to 2017, the share of AstraZeneca, the original research enterprise, was increased from 10